Álvaro González

Dr. Álvaro González

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JMJulia E. Marquez-Arrico
Julia E. Marquez-Arrico
ÁGÁlvaro González
Álvaro González
JNJosé Francisco Navarro
José Francisco Navarro
RPRafael Penadés
Rafael Penadés
Ana AdanAna Adan
Ana Adan
Comorbidity of substance use disorders (SUD) and severe mental illness (SMI) is highly frequent in patients, the most common diagnoses being schizophrenia (SZ), bipolar disorder (BD) and major depressive disorder (MDD). Since comorbidity has its own clinical features, and neurocognitive functioning is not always similar to psychiatric symptoms the present study explores the cognitive performance of patients with dual disorders. A neuropsychological battery of tests was used to assess 120 under treatment male patients, 40 for each group considered (SZ + SUD, BD + SUD and MDD + SUD) who were mainly polyconsumers. Significant differences (with premorbid IQ as a covariate) were found among the groups, with SZ + SUD having a worse performance in attention, verbal learning, short term memory and recognition. The consideration of a global Z score for performance evidenced an impaired neurocognitive pattern for SZ + SUD compared with BD + SUD and MDD + SUD. According to norms, all patients showed difficulties in verbal learning, short-term memory and recognition. Our research indicated that the neurocognitive functioning of dual disorder patients was influenced by the comorbid SMI, with SZ + SUD presenting major difficulties. Future studies should thoroughly explore the role of such difficulties as indicators or endophenotypes for dual schizophrenia disorders, and their usefulness for prevention and treatment.

12 October 2026 in Journal of Affective Disorders Reports
Verified
Journal Article
Open access
ANAdile Nexha
Adile Nexha
ATAndre C. Tonon
Andre C. Tonon
GAGuilherme Rodriguez Amando
Guilherme Rodriguez Amando
ÁGÁlvaro González
Álvaro González
Ana AdanAna Adan
Ana Adan
BFBenicio N. Frey
Benicio N. Frey

11 December 2025 in Irish Journal of Psychological Medicine
Verified
Journal Article
Closed access
ÁGÁlvaro González
Álvaro González
JNJosé Francisco Navarro
José Francisco Navarro
Ana AdanAna Adan
Ana Adan
Objectives: To compare verbal memory encoding, storage, and retrieval in patients with schizophrenia (SZ), SZ plus substance use disorder (SZ+), and substance use disorder only (SUD), testing the hypothesis that SZ + group exhibits greater impairment across all processes. Methods: A total of 294 male patients under treatment (SZ = 72, SZ+ = 72, SUD = 150) meeting DSM-5 criteria completed the Rey Auditory Verbal Learning Test (RAVLT). RAVLT measures assessed encoding, storage, and retrieval. ANCOVA/MANCOVA, controlling for premorbid IQ, were used to explore group differences. Results: Significant differences among groups were observed in all RAVLT measures (F(2,291) > 9.25, p < 0.001, ηp 2 > 0.06) except retrieval. Post hoc analyses revealed that both SZ and SZ+ groups showed significant verbal memory impairments (learning trials and storage, interference, short and long-term recall and recognition) compared to the SUD group which performed within the normative range. The SZ and SZ+ groups showed altered values (Z ≥ −1.5) from the second learning trial onward and total learning, and the SZ+ group also for long-term recall and recognition. Conclusions: This study confirms the existence of significant verbal memory deficits in both SZ and SZ+ groups compared to SUD. Verbal memory impairment appears as a central feature of SZ spectrum disorders, irrespective of SUD comorbidity. Exacerbated memory impairment in SZ+ compared to SZ on the RAVLT is subtle without reaching significant differences, although consideration of altered Z-scores suggests worse performance in SZ+ in encoding and consolidation processes. Further research should explore clinical variables and moderators of comorbidity effects in SZ.